BRPI0511126A - métodos de tratamento utilizando proteìnas de ligação de albumina como alvos - Google Patents

métodos de tratamento utilizando proteìnas de ligação de albumina como alvos

Info

Publication number
BRPI0511126A
BRPI0511126A BRPI0511126-9A BRPI0511126A BRPI0511126A BR PI0511126 A BRPI0511126 A BR PI0511126A BR PI0511126 A BRPI0511126 A BR PI0511126A BR PI0511126 A BRPI0511126 A BR PI0511126A
Authority
BR
Brazil
Prior art keywords
chemotherapeutic agent
targets
treatment methods
binding proteins
albumin binding
Prior art date
Application number
BRPI0511126-9A
Other languages
English (en)
Inventor
Vuong Trieu
Neil P Desai
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35463351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0511126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience Inc filed Critical Abraxis Bioscience Inc
Publication of BRPI0511126A publication Critical patent/BRPI0511126A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)

Abstract

MéTODOS DE TRATAMENTO UTILIZANDO PROTEìNAS DE LIGAçãO DE ALBUMINA COMO ALVOS A invenção provê um método para determinar a sensibilidade de um tumor de mamífero a um agente quimioterapêutico compreendendo detecção e quantificação da proteína SPARC em uma amostra isolada do ser humano. A Invenção também provê um método para distribuição de um agente quimioterapêutico a um tumor em um ser humano que expressa SPARC compreendendo administração de uma composição farmacêutica compreendendo o agente quimioterapêutico acoplado a um composto que se liga à proteína SPARC. A invenção provê, adicionalmente, uma composição compreendendo um agente quimioterapêutico acoplado a um composto capaz de ligação à proteína SPARC e um veículo farmaceuticamente aceitável.
BRPI0511126-9A 2004-05-14 2005-05-16 métodos de tratamento utilizando proteìnas de ligação de albumina como alvos BRPI0511126A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57162204P 2004-05-14 2004-05-14
US65426105P 2005-02-18 2005-02-18
PCT/US2005/017174 WO2005117952A2 (en) 2004-05-14 2005-05-16 Treatment methods utilizing albumin-binding proteins as targets

Publications (1)

Publication Number Publication Date
BRPI0511126A true BRPI0511126A (pt) 2007-11-27

Family

ID=35463351

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511126-9A BRPI0511126A (pt) 2004-05-14 2005-05-16 métodos de tratamento utilizando proteìnas de ligação de albumina como alvos

Country Status (8)

Country Link
EP (3) EP2784082B1 (pt)
JP (1) JP4689666B2 (pt)
CN (2) CN102614521A (pt)
BR (1) BRPI0511126A (pt)
CA (1) CA2566571A1 (pt)
ES (2) ES2662848T3 (pt)
MX (1) MXPA06013191A (pt)
WO (1) WO2005117952A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
AU2006237613A1 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 SPARC deletion mutant and uses thereof
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP5038407B2 (ja) * 2006-06-14 2012-10-03 ジョンズ ホプキンズ ユニバーシティー 疾患のバイオマーカーとしてのアルブミン結合性タンパク質／ペプチド複合体
WO2015081096A2 (en) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
EP2131821B1 (en) * 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2015271950B2 (en) * 2007-03-07 2017-09-28 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2013204187B2 (en) * 2007-03-07 2015-10-01 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
ES2389828T3 (es) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
BRPI0922789A2 (pt) * 2008-12-05 2019-10-15 Abraxis Bioscience Llc peptídeo de ligação de albumina intermediador para reconhecimento de doença
BRPI0923155A2 (pt) * 2008-12-05 2018-10-23 Abraxis Bioscience Llc scfcs de ligação a sparc
JP2013522235A (ja) * 2010-03-11 2013-06-13 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ血管新生領域及びその使用法
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
WO2011137441A2 (en) * 2010-04-30 2011-11-03 Abraxis Bioscience, Llc Sparc binding aptamers and uses thereof
CA2801184A1 (en) * 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Peripheral blood sparc binding antibodies and uses thereof
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
EP3154586B1 (en) * 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
CN109922836A (zh) * 2016-08-05 2019-06-21 梅奥医学教育和研究基金会 用于癌症治疗的经修饰抗体-白蛋白纳米颗粒复合物
CN106755499B (zh) * 2017-01-24 2020-06-30 青岛市畜牧兽医研究所 一种与奶山羊乳体细胞数性状相关的分子标记及其应用
KR20210078512A (ko) * 2018-10-17 2021-06-28 선스테이트 바이오사이언시즈, 엘엘씨 치료 효과 향상을 위한 단일 단백질-캡슐화된 약제
JP7466875B2 (ja) * 2021-02-19 2024-04-15 ソウル大学校産学協力団 Ｓｐａｒｃを発現する癌の治療用組成物
CN113842387A (zh) * 2021-11-19 2021-12-28 大连理工大学盘锦产业技术研究院 10-羟基喜树碱与鹰嘴豆芽素a的药物组合物及其应用
CN118086317B (zh) * 2024-01-12 2025-03-25 深圳市第二人民医院(深圳市转化医学研究院) Sparc蛋白基因调控元件、功能化白蛋白纳米制剂及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20040018188A9 (en) * 1999-01-20 2004-01-29 Incyte Genomics, Inc. Sparc-related proteins
BR0012196A (pt) * 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
CN1240721C (zh) * 2002-12-03 2006-02-08 中国医学科学院医药生物技术研究所 力达霉素与单克隆抗体及其Fab'片段的偶联物以及在结肠癌等肿瘤靶向治疗中的应用
JP2007525167A (ja) * 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
CN102989009B (zh) * 2003-12-31 2015-06-03 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法

Also Published As

Publication number Publication date
EP2784082A1 (en) 2014-10-01
ES2529660T3 (es) 2015-02-24
JP2007537460A (ja) 2007-12-20
CN1980699A (zh) 2007-06-13
EP1755653B1 (en) 2014-12-31
EP1755653A4 (en) 2008-09-03
ES2662848T3 (es) 2018-04-10
CN1980699B (zh) 2012-03-21
MXPA06013191A (es) 2007-07-24
JP4689666B2 (ja) 2011-05-25
EP1755653A2 (en) 2007-02-28
EP2784082B1 (en) 2017-12-27
WO2005117952A3 (en) 2006-04-13
CN102614521A (zh) 2012-08-01
WO2005117952A2 (en) 2005-12-15
CA2566571A1 (en) 2005-12-15
EP3327031A1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
BRPI0511126A (pt) métodos de tratamento utilizando proteìnas de ligação de albumina como alvos
Cantley et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Paez‐Ribes et al. Targeting senescent cells in translational medicine
Jensen et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
Lee et al. A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients
Tohidnezhad et al. Role of platelet-released growth factors in detoxification of reactive oxygen species in osteoblasts
Spenlé et al. Tenascin-C: Exploitation and collateral damage in cancer management
Guenter et al. Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment
Kim et al. Status epilepticus induces vasogenic edema via tumor necrosis factor-α/endothelin-1-mediated two different pathways
Malik et al. Comparison of changes in gene expression of transferrin receptor-1 and other iron-regulatory proteins in rat liver and brain during acute-phase response
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
Wu et al. Salvianolic acid B protects human endothelial cells from oxidative stress damage: a possible protective role of glucose-regulated protein 78 induction
BRPI0416603A (pt) anticorpo que se liga ao receptor interleucina-4 (il-4) humano
PT1282443E (pt) Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
BRPI0622054B8 (pt) composto e composição farmacêutica
Lundsten et al. The HSP90 inhibitor onalespib potentiates 177Lu-DOTATATE therapy in neuroendocrine tumor cells
Johnson et al. The deadly connection between endoplasmic reticulum, Ca2+, protein synthesis, and the endoplasmic reticulum stress response in malignant glioma cells
Maltseva et al. Biodistribution of viscumin after subcutaneous injection to mice and in vitro modeling of endoplasmic reticulum stress
Parks et al. Autophagic flux inhibition and lysosomogenesis ensuing cellular capture and retention of the cationic drug quinacrine in murine models
BR112013023978A2 (pt) "polipeptídeo com afinidade por proteínas de choque térmico e seu uso em diagnóstico de doença infecciosa, produção de resposta imune e tratamento 5 de câncer, bem como ácido nucleico, composição e método de fracionamento de substância para pesquisa ou análise clínica de amostra biológica".
Rotta et al. A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors
Mancini et al. FOXM1 transcription factor: a new component of chronic myeloid leukemia stem cell proliferation advantage
Fu et al. Suppressing chondrocyte cuproptosis by syringaresinol-4-O-β-d-glucoside alleviates gouty arthritis
Wahba et al. Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity
Guo et al. Screening of allergic components mediated by H1R in homoharringtonine injection through H1R/CMC‐HPLC/MS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]